Drug Type Small molecule drug |
Synonyms ALOGLIPTIN AND METFORMIN HYDROCHLORIDE, Alogliptin/metformin, ALOGLIPTIN/METFORMIN HYDROCHLORIDE + [10] |
Target |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors), PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (25 Jan 2013), |
Regulation- |
Molecular FormulaC25H27N5O4 |
InChIKeyKEJICOXJTRHYAK-XFULWGLBSA-N |
CAS Registry850649-62-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | US | 25 Jan 2013 |
Phase 3 | - | 12 | (SYR-322-MET Fasted) | eaqseoqctr(zhvklkrdlv) = ugknuwyrcr yvpxbrjcwu (wzrzjpepln, hvjnuxaahv - kisrgjyhlc) View more | - | 29 Jun 2015 | |
(SYR-322-MET Fed) | eaqseoqctr(zhvklkrdlv) = vixchdxigv yvpxbrjcwu (wzrzjpepln, gawyttqbrr - hdevpoqkke) View more |